ArticleFrontiers in allergy2025
Association of intestinal barrier impairment with symptom severity and washed microbiota transplantation outcomes in atopic dermatitis patients.
Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-invasive detection of pediatric atopic dermatitis based on fecal microbiota and metabolite profiles: a diagnostic approach.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We hypothesized that intestinal barrier impairment is a key pathophysiological feature in AD and that the degree of baseline barrier dysfunction, reflected by serum D-lactate levels, predicts the clinical response to Washed Microbiota Transplantation (WMT). This study aimed to test these hypotheses by investigating the association between intestinal barrier biomarkers and AD severity, and their correlation with WMT outcomes. Methods: We compared intestinal barrier biomarkers (D-lactate, endotoxin, and diamine oxidase) between 24 AD patients and 23 healthy donors. Additionally, we evaluated the clinical outcomes of 14 AD patients who underwent WMT therapy. Results: AD patients exhibited significantly elevated intestinal barrier biomarkers compared to healthy donors ( Conclusion: This study confirms significant intestinal barrier dysfunction in AD and demonstrates the potential clinical efficacy of WMT. The strong, uncorrected correlations suggest that pre-treatment D-lactate level warrants further investigation as a candidate biomarker for predicting WMT response. The clinical benefits occurred alongside a restructuring of the gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.